The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...

Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...

Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary ...